Arrowhead Pharmaceuticals (ARWR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 12. Analyst Mani Foroohar from Leerink Partners reiterated a Hold rating on the stock and has a $22.00 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Mani Foroohar has given his Hold rating due to a combination of factors including Arrowhead Pharmaceuticals’ current financial position and its pipeline developments. The company reported strong revenue for the second quarter of 2025, largely driven by a significant upfront contract and equity investment, which positions it well financially with $1.1 billion in cash. This financial strength is expected to support the company’s operations through 2028.
However, despite the robust financials, there are uncertainties surrounding the company’s pipeline progress. While there are several promising developments expected, such as the upcoming PDUFA date for plozasiran and various trial initiations, these are balanced by competitive pressures and the inherent risks of drug development. Additionally, the company is in the process of managing its debt, which could impact future financial flexibility. These factors together justify a Hold rating, reflecting a cautious optimism about the company’s future prospects.
Foroohar covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, RegenXBio, and Tenaya Therapeutics. According to TipRanks, Foroohar has an average return of -13.1% and a 38.70% success rate on recommended stocks.
In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $29.00 price target.